Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

Robert Chapman; Loretta Itri; Richard Gralla; David Kelsen; Ephraim Casper; Robert Golbey

doi:10.1007/BF00254550

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

Robert Chapman, Loretta Itri, Richard Gralla, David Kelsen, Ephraim Casper, Robert Golbey

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

Original language	English (US)
Pages (from-to)	205-207
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	7
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00254550
State	Published - Apr 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00254550

Cite this

@article{12b7bfa2c8764a369d175eef546d0f74,

title = "Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)",

abstract = "Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.",

author = "Robert Chapman and Loretta Itri and Richard Gralla and David Kelsen and Ephraim Casper and Robert Golbey",

year = "1982",

month = apr,

doi = "10.1007/BF00254550",

language = "English (US)",

volume = "7",

pages = "205--207",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2-3",

}

TY - JOUR

T1 - Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

AU - Chapman, Robert

AU - Itri, Loretta

AU - Gralla, Richard

AU - Kelsen, David

AU - Casper, Ephraim

AU - Golbey, Robert

PY - 1982/4

Y1 - 1982/4

N2 - Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

AB - Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0020040619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020040619&partnerID=8YFLogxK

U2 - 10.1007/BF00254550

DO - 10.1007/BF00254550

M3 - Article

C2 - 7083460

AN - SCOPUS:0020040619

SN - 0344-5704

VL - 7

SP - 205

EP - 207

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2-3

ER -

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this